Piramal Pharma Ltd

Piramal Pharma's shares reached a fresh 52-week low of Rs.177.6 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past three consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Piramal Pharma's shares touched a fresh 52-week low of Rs.177.6 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past three consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Piramal Pharma's shares touched a fresh 52-week low of Rs.177.6 today, marking a significant decline amid a three-day losing streak that has seen the stock fall by 3.59%. This performance contrasts sharply with the broader market, where the Sensex closed marginally higher, underscoring the stock's ongoing challenges within the Pharmaceuticals & Biotechnology sector.

Piramal Pharma’s shares touched a fresh 52-week low of Rs.180.1 today, marking a significant decline amid subdued financial performance and persistent downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about profitability and debt servicing capacity.

Piramal Pharma's stock price momentum has shifted towards a more bearish technical outlook, reflecting a series of signals from key indicators such as MACD, RSI, and moving averages. The pharmaceutical and biotechnology company’s recent price action and technical parameters suggest a cautious stance for investors amid broader market dynamics.

Piramal Pharma has undergone a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. The changes stem from a combination of factors including its current financial performance, valuation metrics, and technical indicators, all of which have influenced investor sentiment in the Pharmaceuticals & Biotechnology sector.

Piramal Pharma has undergone a revision in its market evaluation reflecting recent developments in its financial and technical parameters. The pharmaceutical company’s assessment now indicates a more cautious outlook, driven by a combination of valuation concerns, financial trends, and technical indicators.

Piramal Pharma Ltd. reported a consolidated net loss of ₹99.22 crores for Q2 FY26, marking a significant deterioration from the ₹22.59 crores profit posted in the year-ago quarter. The pharmaceutical company, with a market capitalisation of ₹27,269.53 crores, saw its operating margins compress sharply to 7.76% from 15.24% in Q2 FY25, reflecting mounting operational challenges. The stock traded at ₹205.15 on November 6, down 30.11% over the past year, substantially underperforming both the broader market and the pharmaceuticals sector.

Piramal Pharma, a small-cap in the Pharmaceuticals and Biotechnology sector, has experienced a significant decline over the past year, underperforming compared to the Sensex. Technical indicators present a mixed outlook, with recent performance showing modest gains but overall struggles year-to-date, highlighting ongoing market challenges.

Piramal Pharma, a small-cap pharmaceutical company, has seen its stock price rise slightly, reflecting notable volatility over the past year. Technical indicators present mixed signals, while the stock has outperformed the Sensex in recent weeks but lags behind in year-to-date and three-year performance metrics.